Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.13
OCR's Cash to Debt is ranked higher than
67% of the 302 Companies
in the Global Medical Care industry.

( Industry Median: 0.19 vs. OCR: 0.13 )
OCR' s 10-Year Cash to Debt Range
Min: 0.05   Max: 67.66
Current: 0.13

0.05
67.66
Equity to Asset 0.42
OCR's Equity to Asset is ranked higher than
73% of the 303 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. OCR: 0.42 )
OCR' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.88
Current: 0.42

0.31
0.88
F-Score: 5
Z-Score: 2.83
M-Score: -2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 8.48
OCR's Operating margin (%) is ranked higher than
76% of the 305 Companies
in the Global Medical Care industry.

( Industry Median: 8.59 vs. OCR: 8.48 )
OCR' s 10-Year Operating margin (%) Range
Min: 1.33   Max: 12.02
Current: 8.48

1.33
12.02
Net-margin (%) 1.09
OCR's Net-margin (%) is ranked higher than
65% of the 305 Companies
in the Global Medical Care industry.

( Industry Median: 4.91 vs. OCR: 1.09 )
OCR' s 10-Year Net-margin (%) Range
Min: -1.73   Max: 8.11
Current: 1.09

-1.73
8.11
ROE (%) 2.38
OCR's ROE (%) is ranked higher than
63% of the 286 Companies
in the Global Medical Care industry.

( Industry Median: 9.56 vs. OCR: 2.38 )
OCR' s 10-Year ROE (%) Range
Min: -2.76   Max: 13.17
Current: 2.38

-2.76
13.17
ROA (%) 1.01
OCR's ROA (%) is ranked higher than
65% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 3.52 vs. OCR: 1.01 )
OCR' s 10-Year ROA (%) Range
Min: -1.44   Max: 8.04
Current: 1.01

-1.44
8.04
ROC (Joel Greenblatt) (%) 38.76
OCR's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 305 Companies
in the Global Medical Care industry.

( Industry Median: 18.24 vs. OCR: 38.76 )
OCR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.04   Max: 87.29
Current: 38.76

5.04
87.29
Revenue Growth (%) 1.50
OCR's Revenue Growth (%) is ranked higher than
64% of the 239 Companies
in the Global Medical Care industry.

( Industry Median: 6.10 vs. OCR: 1.50 )
OCR' s 10-Year Revenue Growth (%) Range
Min: -0.4   Max: 42.3
Current: 1.5

-0.4
42.3
EBITDA Growth (%) 29.10
OCR's EBITDA Growth (%) is ranked higher than
96% of the 191 Companies
in the Global Medical Care industry.

( Industry Median: 6.50 vs. OCR: 29.10 )
OCR' s 10-Year EBITDA Growth (%) Range
Min: -21.8   Max: 37.6
Current: 29.1

-21.8
37.6
EPS Growth (%) 86.60
OCR's EPS Growth (%) is ranked higher than
95% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 10.90 vs. OCR: 86.60 )
OCR' s 10-Year EPS Growth (%) Range
Min: -49.6   Max: 86.6
Current: 86.6

-49.6
86.6
» OCR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

OCR Guru Trades in Q4 2013

Pioneer Investments 315,295 sh (New)
Jim Simons 248,000 sh (+174.94%)
Steven Cohen 8,361 sh (+54.01%)
James Barrow 4,506,812 sh (+1.25%)
Chuck Royce 67,299 sh (+0.6%)
Jean-Marie Eveillard 851,300 sh (unchged)
Wallace Weitz Sold Out
Steven Romick Sold Out
Joel Greenblatt 11,932 sh (-86.3%)
First Pacific Advisors 1,100 sh (-99.87%)
» More
Q1 2014

OCR Guru Trades in Q1 2014

Paul Tudor Jones 232,334 sh (New)
Steven Cohen 34,457 sh (+312.12%)
Jim Simons 482,300 sh (+94.48%)
Pioneer Investments 515,458 sh (+63.48%)
James Barrow 4,800,283 sh (+6.51%)
First Pacific Advisors Sold Out
Jean-Marie Eveillard 846,300 sh (-0.59%)
Chuck Royce 59,999 sh (-10.85%)
Joel Greenblatt 3,386 sh (-71.62%)
» More
Q2 2014

OCR Guru Trades in Q2 2014

Joel Greenblatt 48,646 sh (+1336.68%)
Pioneer Investments 689,748 sh (+33.81%)
James Barrow 4,996,755 sh (+4.09%)
Jean-Marie Eveillard 844,500 sh (-0.21%)
Chuck Royce 56,599 sh (-5.67%)
Jim Simons 454,900 sh (-5.68%)
Paul Tudor Jones 100,564 sh (-56.72%)
» More
Q3 2014

OCR Guru Trades in Q3 2014

Ray Dalio 5,634 sh (New)
Joel Greenblatt 501,043 sh (+929.98%)
Jim Simons 1,125,800 sh (+147.48%)
Pioneer Investments 705,443 sh (+2.28%)
James Barrow 5,059,633 sh (+1.26%)
Jean-Marie Eveillard 844,500 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 52,399 sh (-7.42%)
» More
» Details

Insider Trades

Latest Guru Trades with OCR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 929.98%0.28%$61.43 - $66.49 $ 70.6311%501043
Ray Dalio 2014-09-30 New Buy$61.43 - $66.49 $ 70.6311%5634
Joel Greenblatt 2014-06-30 Add 1336.68%0.04%$57.54 - $66.51 $ 70.6314%48646
Joel Greenblatt 2014-03-31 Reduce -71.62%0.01%$56.55 - $64.54 $ 70.6316%3386
Wallace Weitz 2013-12-31 Sold Out 0.24%$53.81 - $60.39 $ 70.6323%0
Joel Greenblatt 2013-12-31 Reduce -86.3%0.14%$53.81 - $60.39 $ 70.6323%11932
Wallace Weitz 2013-09-30 Reduce -84.78%1.19%$47.68 - $56.28 $ 70.6332%113700
Jean-Marie Eveillard 2013-09-30 Reduce -55.65%0.16%$47.68 - $56.28 $ 70.6332%851300
Joel Greenblatt 2013-09-30 New Buy0.16%$47.68 - $56.28 $ 70.6332%87071
Wallace Weitz 2013-06-30 Reduce -52.62%1.37%$40.82 - $47.97 $ 70.6358%746920
HOTCHKIS & WILEY 2013-06-30 Sold Out 0.29%$40.82 - $47.97 $ 70.6358%0
Joel Greenblatt 2013-06-30 Sold Out 0.25%$40.82 - $47.97 $ 70.6358%0
Joel Greenblatt 2013-03-31 New Buy0.25%$36.1 - $40.72 $ 70.6383%122850
Joel Greenblatt 2012-12-31 Sold Out 0.02%$32.98 - $36.59 $ 70.63103%0
Joel Greenblatt 2012-09-30 Reduce -80.66%0.1%$30.68 - $35.53 $ 70.63119%10660
Joel Greenblatt 2012-06-30 New Buy0.13%$29.5 - $36.01 $ 70.63113%55131
Ray Dalio 2012-06-30 Sold Out 0.06%$29.5 - $36.01 $ 70.63113%0
HOTCHKIS & WILEY 2012-03-31 Add 374.68%0.23%$32.51 - $35.56 $ 70.63122%1376484
Joel Greenblatt 2012-03-31 Sold Out 0.2%$32.51 - $35.56 $ 70.63122%0
Ray Dalio 2012-03-31 Add 1622.17%0.05%$32.51 - $35.56 $ 70.63122%101281
HOTCHKIS & WILEY 2011-12-31 New Buy0.07%$21.62 - $35.05 $ 70.63136%289984
David Dreman 2011-12-31 Sold Out 0.06%$21.62 - $35.05 $ 70.63136%0
Joel Greenblatt 2011-12-31 Reduce -20.99%0.05%$21.62 - $35.05 $ 70.63136%47467
Ray Dalio 2011-12-31 New Buy$21.62 - $35.05 $ 70.63136%5881
Joel Greenblatt 2011-09-30 Add 239.78%0.18%$25.21 - $32.98 $ 70.63142%60077
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Omnicare Inc

Steven Romick Comments on Omnicare - Jul 29, 2013

Ultimately, we pay more attention to the underlying financial performance of the companies in our investment portfolio than we do their stock charts and in one instance, Omnicare (OCR), the largest supplier of pharmaceuticals to patients in nursing homes, delivered in spades. New management came in several years ago and began executing on a business plan that revolved around basic blocking and tackling to improve performance. While the engineer of the turnaround, John Figueroa, has handed off the plan to his successor, the momentum remained intact under the present CEO, John Workman. The company has lowered costs, reduced customer churn, won new accounts and essentially built the best mousetrap in the institutional pharmacy space. The net result is that all of the aforementioned improvements in aggregate have manifested themselves in the form of higher and more consistent earnings. Those achievements and the belief that the company's future continues to look bright are reflected in a stock price that has more than doubled from our original cost.

From Steven Romick's FPA Crescent Fund second quarter commentary.
Check out Steven Romick latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 122.40
OCR's P/E(ttm) is ranked higher than
67% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 43.60 vs. OCR: 122.40 )
OCR' s 10-Year P/E(ttm) Range
Min: 10.93   Max: 122.41
Current: 122.4

10.93
122.41
P/B 2.60
OCR's P/B is ranked higher than
75% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 2.96 vs. OCR: 2.60 )
OCR' s 10-Year P/B Range
Min: 0.6   Max: 2.97
Current: 2.6

0.6
2.97
P/S 1.23
OCR's P/S is ranked higher than
76% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 1.55 vs. OCR: 1.23 )
OCR' s 10-Year P/S Range
Min: 0.33   Max: 1.43
Current: 1.23

0.33
1.43
PFCF 27.17
OCR's PFCF is ranked higher than
82% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 85.90 vs. OCR: 27.17 )
OCR' s 10-Year PFCF Range
Min: 4.79   Max: 71.06
Current: 27.17

4.79
71.06
EV-to-EBIT 17.02
OCR's EV-to-EBIT is ranked higher than
82% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 22.71 vs. OCR: 17.02 )
OCR' s 10-Year EV-to-EBIT Range
Min: 8.9   Max: 69.6
Current: 17.02

8.9
69.6
PEG 5.25
OCR's PEG is ranked higher than
87% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. OCR: 5.25 )
OCR' s 10-Year PEG Range
Min: 0.67   Max: 134.53
Current: 5.25

0.67
134.53
Shiller P/E 89.17
OCR's Shiller P/E is ranked higher than
78% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 1193.86 vs. OCR: 89.17 )
OCR' s 10-Year Shiller P/E Range
Min: 9.36   Max: 89.47
Current: 89.17

9.36
89.47
Current Ratio 1.92
OCR's Current Ratio is ranked higher than
87% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 1.34 vs. OCR: 1.92 )
OCR' s 10-Year Current Ratio Range
Min: 0.9   Max: 9.8
Current: 1.92

0.9
9.8
Quick Ratio 1.39
OCR's Quick Ratio is ranked higher than
79% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 1.21 vs. OCR: 1.39 )
OCR' s 10-Year Quick Ratio Range
Min: 0.73   Max: 9.04
Current: 1.39

0.73
9.04

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.13
OCR's Dividend Yield is ranked lower than
67% of the 178 Companies
in the Global Medical Care industry.

( Industry Median: 1.47 vs. OCR: 1.13 )
OCR' s 10-Year Dividend Yield Range
Min: 0.15   Max: 1.32
Current: 1.13

0.15
1.32
Dividend Payout 0.34
OCR's Dividend Payout is ranked higher than
86% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. OCR: 0.34 )
OCR' s 10-Year Dividend Payout Range
Min: 0.03   Max: 0.95
Current: 0.34

0.03
0.95
Dividend growth (3y) 78.00
OCR's Dividend growth (3y) is ranked higher than
98% of the 120 Companies
in the Global Medical Care industry.

( Industry Median: 8.60 vs. OCR: 78.00 )
OCR' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 78
Current: 78

0
78
Yield on cost (5-Year) 14.81
OCR's Yield on cost (5-Year) is ranked higher than
97% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 2.11 vs. OCR: 14.81 )
OCR' s 10-Year Yield on cost (5-Year) Range
Min: 2.02   Max: 17.77
Current: 14.81

2.02
17.77
Share Buyback Rate 2.20
OCR's Share Buyback Rate is ranked higher than
93% of the 194 Companies
in the Global Medical Care industry.

( Industry Median: -1.40 vs. OCR: 2.20 )
OCR' s 10-Year Share Buyback Rate Range
Min: 2.2   Max: -15.6
Current: 2.2

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.23
OCR's Price/DCF (Projected) is ranked higher than
86% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 4.19 vs. OCR: 1.23 )
OCR' s 10-Year Price/DCF (Projected) Range
Min: 0.39   Max: 7
Current: 1.23

0.39
7
Price/Median PS Value 1.84
OCR's Price/Median PS Value is ranked higher than
59% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 1.26 vs. OCR: 1.84 )
OCR' s 10-Year Price/Median PS Value Range
Min: 0.53   Max: 6.84
Current: 1.84

0.53
6.84
Price/Peter Lynch Fair Value 3.36
OCR's Price/Peter Lynch Fair Value is ranked higher than
88% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. OCR: 3.36 )
OCR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.48   Max: 12.4
Current: 3.36

0.48
12.4
Earnings Yield (Greenblatt) 5.90
OCR's Earnings Yield (Greenblatt) is ranked higher than
80% of the 302 Companies
in the Global Medical Care industry.

( Industry Median: 4.80 vs. OCR: 5.90 )
OCR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 11.3
Current: 5.9

1.4
11.3
Forward Rate of Return (Yacktman) 13.27
OCR's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 246 Companies
in the Global Medical Care industry.

( Industry Median: 9.05 vs. OCR: 13.27 )
OCR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.3   Max: 23.1
Current: 13.27

-5.3
23.1

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Traded in other countries:OMN.Germany
Omnicare Inc was formed in 1981. It is a healthcare services company that provides complex pharmaceutical care. It operates in two primary businesses, Long-Term Care Group (LTC) and Specialty Care Group (SCG). Through LTC, the Company provides pharmaceuticals and related pharmacy and ancillary services to long-term care facilities as well as chronic care facilities and other settings. SCG provides commercialization services for the biopharmaceutical industry in addition to end-of-life pharmaceutical care management for hospice care agencies. With respect to its clinical services, the Company provides pharmacy consulting, including monthly patient drug therapy evaluations, assist in compliance with state and federal regulations and provide proprietary clinical and health management programs. LTC also provides a suite of technology solutions based on its Omniview web-based platform that is intended to improve the efficiency of its customers' operations through such tools as the electronic ordering of prescription refills, proof-of-delivery tracking, and real-time validation of Medicare Part D coverage, among others. LTC also provides a number of other products and services, including intravenous medications and nutrition products (infusion therapy products and services), respiratory therapy services, medical supplies and equipment (including billing the Medicare Part B program for eligible patients) and clinical care planning. The Company also provides pharmaceutical case management services for retirees, employees and dependents who have drug benefits under corporate-sponsored healthcare programs. SCG touches a broad spectrum of the healthcare continuum, serving the needs of biopharmaceutical manufacturers, physicians, nurses, caregivers and patients. Its services are largely centered on the specialty pharmaceutical market. These services are based on five platforms: brand support services, third party logistics, patient assistance programs, specialty pharmacy and disease management for end-of-life care. Its brand support services, third party logistics and patient assistance programs are integrated, fee-for-service platforms which focus on helping the drug manufacturer to market, to distribute and obtain reimbursement for their products. In its specialty pharmacy platform, the Company provides dispensing of specialized pharmaceuticals that are high cost, have complex reimbursement and supply chain challenges, have limited patient populations and are not available through normal retail channels. These specialized drugs deal primarily with specific categories of drugs and disease states, such as rheumatoid arthritis, multiple sclerosis, oncology and growth hormones. LTC's customers consist of skilled nursing facilities, assisted living facilities, independent living communities, hospitals, correctional facilities, and other healthcare service providers. The Company's largest competitor nationally is PharMerica Corporation. It also
» More Articles for OCR

Headlines

Articles On GuruFocus.com
It's Time to Follow Chris Davis and Buy Laboratory Corp Jan 15 2014 
Steven Romick’s Third Quarter Sells at FPA Crescent Fund Oct 17 2013 
Waiting for Gold Rain, Wally Weitz Does "Unnaturally Well" Sep 23 2013 
First Pacific Advisors’ Major Selling and Reductions in Second Quarter Aug 15 2013 
Steven Romick Comments on Omnicare Jul 29 2013 
Steven Romick on WealthTrack Oct 20 2012 
Weekly CEO Buys Highlight: SYMC, TDY, PNK, FNFG, OCR Aug 04 2012 
Weitz Partners Value Fund Commentary: CVS, TGT, BRK.A, BRK.B Nov 11 2011 
Daily Dividend Report: HNZ, OCR, SEIC, FPTB, EDE, FISI May 26 2011 
Wallace Weitz Finds Value in These Stocks: LINTA, OCR, RWT, BRK.B, LBTYK, MSFT Dec 14 2010 

More From Our Partners
How to Uncover Institutional Buying - Screen of the Week Nov 18 2014 - ZACKS

More From Other Websites
OMNICARE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Nov 21 2014
OMNICARE INC Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 18 2014
Omnicare Announces Conversion Rate Adjustment for Convertible Notes Nov 11 2014
Omnicare Announces Conversion Rate Adjustment for Convertible Notes Nov 11 2014
Today's Stocks Driving Success For The Wholesale Industry Nov 11 2014
Omnicare Announces Conversion Rate Adjustment for Convertible Notes Nov 11 2014
OMNICARE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 10 2014
OMNICARE INC Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 07 2014
Omnicare Announces Pricing of Senior Notes Offering Nov 06 2014
Omnicare Announces Pricing of Senior Notes Offering Nov 06 2014
Omnicare Announces Pricing of Senior Notes Offering Nov 06 2014
Omnicare to Present at the Credit Suisse 2014 Health Care Conference Nov 06 2014
Omnicare to Present at the Credit Suisse 2014 Health Care Conference Nov 06 2014
Omnicare to Present at the Credit Suisse 2014 Health Care Conference Nov 06 2014
Omnicare Announces Public Offering of Senior Notes Nov 05 2014
Omnicare Announces Public Offering of Senior Notes Nov 05 2014
Omnicare Announces Public Offering of Senior Notes Nov 05 2014
OMNICARE INC Files SEC form 8-K, Other Events Nov 05 2014
Omnicare Specialty Care Group to Provide Specialty Support Services for New Treatment for IPF - OFEV... Nov 04 2014
Omnicare Specialty Care Group to Provide Specialty Support Services for New Treatment for IPF - OFEV... Nov 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK